Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

Peru: These 17 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "Peru: These 17 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Peru Patent 20,080,852
Patent Title: POLIMORFOS DE N-HIDROXI-3-[4-[[[2-(2-METIL-1H-INDOL-3-IL)ETIL]AMINO]METIL]FENIL]-2E-2-PROPENAMIDA

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can JESDUVROQ (daprodustat) generic drug versions launch?

Generic name: daprodustat
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Peru Patent 20,080,209
Patent Title: DERIVADOS DE GLICINA COMO INHIBIDORES DE PROLIL HIDROXILASA

JESDUVROQ is a drug marketed by Glaxosmithkline. There are six patents protecting this drug.

This drug has forty-four patent family members in thirty-one countries.

See drug price trends for JESDUVROQ.

The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this generic product. Additional details are available on the daprodustat profile page.

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: Peru Patent 20,080,373
Patent Title: FORMULACIONES DE ALISQUIRENO E HIDROCLOROTIAZIDA

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

When can EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) generic drug versions launch?

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2026
Generic Entry Controlled by: Peru Patent 20,080,991

EXFORGE HCT is a drug marketed by Novartis.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

When can EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) generic drug versions launch?

When can BYDUREON (exenatide synthetic) generic drug versions launch?

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,080,349

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch?

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,120,776

When can FARXIGA (dapagliflozin) generic drug versions launch?

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,080,349

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Thirteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-five patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch?

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,120,776

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,080,349

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Peru Patent 20,120,776

When can DAKLINZA (daclatasvir dihydrochloride) generic drug versions launch?

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 11, 2026
Generic Entry Controlled by: Peru Patent 20,080,542
Patent Title: INHIBIDORES DEL VIRUS DE LA HEPATITIS C

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

When can BEVYXXA (betrixaban) generic drug versions launch?

Generic name: betrixaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2026
Generic Entry Controlled by: Peru Patent 20,070,717
Patent Title: SAL DE MALEATO Y POLIMORFO DE [2-({4-[(DIMETILAMINO)IMINOMETIL]FENIL}CARBONILAMINO)-5-METOXIFENIL]-N-(5-CLORO-(2-PIRIDIL))CARBOXAMIDA

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch?

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Peru Patent 20,081,350

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Peru Patent 20,081,447
Patent Title: COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA PROTEINA CINASA

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Peru Patent 20,120,814
Patent Title: COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA PROTEINA CINASA

When can NESINA (alogliptin benzoate) generic drug versions launch?

Generic name: alogliptin benzoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Peru Patent 20,081,734
Patent Title: COMPRIMIDO QUE COMPRENDE 2-[[6-[(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-BENZONITRILO Y CELULOSA MICROCRISTALINA

NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch?

Generic name: rolapitant hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Peru Patent 20,081,891
Patent Title: FORMULACIONES DE COMPRIMIDOS QUE CONTIENEN SALES DE 8-[{1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONA Y COMPRIMIDOS ELABORADOS A PARTIR DE ESTAS

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-five countries.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch?

Generic name: azilsartan kamedoxomil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Peru Patent 20,090,550
Patent Title: COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE UN DERIVADO DE BENCIMIDAZOL Y UN AGENTE DE CONTROL DE PH

EDARBI is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch?

Generic name: azilsartan kamedoxomil
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Peru Patent 20,130,210
Patent Title: COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE UN DERIVADO DE BENCIMIDAZOL Y UN AGENTE DE CONTROL DE PH

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Peru Patent 20,080,773
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE BIS-(MONOETANOLAMINA) DE ACIDO 3'-[(2Z)-[1-(3,4-DIMETILFENIL)-1,5-DIHIDRO-3-METIL-5-OXO-4H-PIRAZOL-4-ILIDENO]HIDRAZINO]-2'-HIDROXI-[1,1'-BIFENIL]-3-CARBOXILICO

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Peru Patent 20,151,953
Patent Title: COMPOSICION FARMACEUTICA QUE COMPRENDE BIS-(MONOETANOLAMINA) DE ACIDO 3'-[(2Z)-[1-(3, 4-DIMETILFENIL)-1, 5-DIHIDRO-3-METIL-5-OXO-4H-PIRAZOL-4-ILIDENO] HIDRAZINO]-2'-HIDROXI-[1, 1'-BIFENIL]-3-CARBOXILICO

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Peru Patent 20,090,387
Patent Title: FORMULACION DE PASIREOTIDA

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has one hundred and thirty-five patent family members in forty-one countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 22, 2027
Generic Entry Controlled by: Peru Patent 20,120,990
Patent Title: FORMULACIONES DE ALISQUIRENO E HIDROCLOROTIAZIDA

Last updated: December 28, 2025

Executive Summary

Peru’s pharmaceutical market is experiencing dynamic growth driven by expanding healthcare coverage, increased government healthcare expenditure, and demographic shifts toward an aging population. The combined effect fosters favorable opportunities for both branded and generic drug manufacturers. However, the market landscape is confronted with regulatory complexities, procurement challenges, and intellectual property considerations that impact market entry and sustainability.

This comprehensive assessment explores Peru's market size, competitive landscape, regulatory framework, opportunities, and hurdles, providing actionable insights for industry players aiming to navigate and capitalize on this evolving environment.

Market Overview: Size and Segmentation

Aspect	Data / Insights
Total Pharmaceutical Market (2022)	USD 1.2 billion (approximate, derived from IQVIA 2022)
Compound Annual Growth Rate (CAGR)	~6% from 2018-2022
Market Segmentation	- Branded drugs: ~55% of total market
	- Generic drugs: ~45% of total market
Major Disease Burdens	Cardiovascular, diabetes, infectious diseases, oncology
Healthcare Coverage	Public sector: 70%; Private sector: 30%
Key Drivers	Government procurement policies, increasing health access, demographic shifts

Market Dynamics

Peru's pharmaceutical market growth mirrors regional Latin American trends but is distinguished by a relatively high penetration of generics (~45%), driven by policies promoting affordability and access.
Public procurement remains a significant market driver, accounting for approximately 60% of drug purchases, emphasizing the importance of regulatory pathways for government procurement.

Regulatory Framework Overview

Key Regulatory Authorities

Authority	Responsibilities	Key Publications / Acts
DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)	Main regulator overseeing drug registration, quality, importation, and distribution	Ley N° 29344 (General Law of Health, 2010)
MINSA (Ministerio de Salud)	Implements health policies, drug pricing, and public procurement	Decreto Supremo N° 017-2014-SA
Sunat (Superintendencia Nacional de Administración Tributaria)	Customs and tax regulation, including import duties	Ley N° 27751

Drug Registration Process

Application submission: dossier includes manufacturing info, stability data, quality assurance, and safety profiles.
Evaluation timeline: approximately 60-120 days.
Additional requirements:
- Good Manufacturing Practice (GMP) certification.
- Local importer/license holder registration.
- Market authorization approval for both branded and generic drugs.

Intellectual Property (IP) and Patent Landscape

Peru adheres to the Andean Community’s IP treaties.
Patents generally valid for 20 years from filing, but patent linkage protections are limited.
Data exclusivity for innovative drugs is not explicitly mandated.
Patent challenges or compulsory licensing are permissible under public health considerations, creating an environment that could impact brand exclusivity.

Market Entry Opportunities

Branded Drugs

Opportunities	Details
Specialty and Innovative Drugs	Launch of innovative therapies, especially in oncology and rare diseases
Public Sector Contracts	Participation in tenders for large-scale public procurement
Strategic Partnerships	Collaborations with local manufacturers for technology transfer

Generic Drugs

Opportunities	Details
Cost-Effective Monotherapy and Fixed-Dose Combinations	Increasing demand in chronic disease management
Market Penetration via Local Production	Local manufacturing to reduce import taxes and improve supply chain stability
Utilization of the Health System’s procurement backbone	Integration into national tenders, e.g., SIS (Seguro Integral de Salud)

Regulatory Opportunities

Fast-track approvals for generics via abridged registration pathways.
Recognition of WHO Prequalification to expedite registration for products meeting global standards.
Potential for market exclusivity on orphan drugs or new chemical entities through regulatory incentives.

Market Challenges and Barriers

Regulatory Challenges

Barrier	Explanation
Lengthy Approval Timelines	Registration process can extend beyond 120 days, impacting time-to-market
Complex Documentation Requirements	Diverse dossier requirements increase pre-market costs and delays
Limited Recognition of Foreign Data	Reliance on local data; foreign data may need local bridging studies
Stringent Quality Control Standards	Ensuring compliance with GMP standards for imported and local products

Market and Economic Risks

Challenge	Impact
Procurement Cancellations / Delays	Affect supply continuity and sales forecasts
Currency and Import Duty Fluctuations	Increased costs and margin pressure
Price Regulation and Reimbursement Policies	Impact on profit margins and market penetration

Intellectual Property and Patent Risks

Risk of patent litigation or compulsory licensing, especially for innovative or branded drugs.
Limited patent term extensions or exclusivity periods compared to other jurisdictions.

Distribution and Access

Complex distribution networks with varied regional regulations.
Challenges reaching remote or underserved areas.

Comparison: Branded vs. Generic Market Dynamics

Aspect	Branded Drugs	Generic Drugs
Market Penetration	Lower, reliant on physician or specialist preference	Higher, driven by price-sensitive healthcare policies
Regulatory Pathway	Lengthier, requires comprehensive dossier	Quicker, possible abbreviated registration pathways
Pricing Strategy	Premium pricing, brand loyalty	Competitive, under government price controls
Market Growth	Moderate, dependent on innovation and exclusivity	High, driven by demand for affordability
Local Manufacturing Incentives	Less prevalent, focus on innovation	Strong, with government policies favoring local production

Regulatory Opportunities and Policy Trends

Policy / Initiative	Impact on Market	Details
Public Procurement Frameworks	Facilitates market access via tenders	Government tenders favor cost-effective generics
Pharmaceutical Price Regulation	May limit pricing flexibility	Binding maximum prices, negotiations with regulators
Patent and Data Exclusivity Policies	Potential protections for innovators	Limited data exclusivity duration (~5 years) in some cases
Local Manufacturing Incentives	Reduces import costs, fosters domestic industry	Tax breaks, subsidies, and quality support programs
WHO PQ Recognition	Accelerates registration for prequalified products	Infrastructure developments to facilitate approvals

Deep-Dive: Comparing Peru’s Pharma Regulation to Regional Neighbors

Criterion	Peru	Colombia	Brazil	Chile
Approval Timeline	60-120 days	60 days (average)	90-180 days	90 days
Patent Recognition	Limited	Similar	Strong, with patent linkage	Moderate
Market Size (2022)	USD 1.2 billion	USD 1.8 billion	USD 4.3 billion	USD 600 million
Public Procurement Share	60%	70%	50%	50%
Local Manufacturing Incentives	Growing, 20% of market share	Moderate	Strong, 25% of market share	Emerging

Peru's registration and patent landscape place it below regional leaders like Brazil but offers flexibility advantageous for first-movers and generic producers.

Key Regulatory Opportunities & Challenges Summary Table

Opportunity / Challenge	Description	Strategic Implication
Fast-track registration for generics	Abbreviated pathways to expedite approvals	Accelerates market entry, minimizes delays
Recognition of global quality standards	WHO PQ and similar certifications	Builds credibility and reduces review times
Patent challenges and compulsory licensing	Possible under public health crises	Need for IP strategy and compliance planning
Local manufacturing policies	Incentives favoring domestic production	Leverage to reduce costs and improve supply chain
Price controls and reimbursement policies	Capping drug prices and coverage schemes	Define pricing strategies and profit margins

Conclusion and Strategic Recommendations

Peru’s pharmaceutical market offers compelling growth and access opportunities, especially in generics, with regulatory pathways amenable to timely market entry. However, industry players must navigate a complex regulatory landscape, with potential delays and compliance hurdles. Local manufacturing incentives, recognition of international standards, and strategic engagement with government procurement frameworks are critical to building sustainable presence.

Effective IP management and understanding domestic policy trajectories will mitigate risks associated with patent exposure and pricing regulation. Emphasizing quality, affordability, and compliance will enable companies to exploit Peru’s evolving healthcare landscape.

Key Takeaways

Growth opportunities abound in the generic sector, driven by government procurement policies and healthcare system expansion.
Regulatory pathways favor expedited approval of generics through recognition of WHO standards and abbreviated processes.
Intellectual property: Limited protections create both challenges and opportunities for generic manufacturers but necessitate careful IP strategy.
Local manufacturing incentives support domestic industry growth; establishing local production can optimize costs and supply security.
Monitoring regulatory and policy updates is essential, especially concerning patent laws, price controls, and public tenders, to adapt strategies proactively.

FAQs

1. How long does drug registration typically take in Peru?
Approval timelines average 60-120 days, subject to the completeness of documentation and compliance with GMP standards.

2. What are the key regulatory agencies for drug approval in Peru?
DIGEMID is the primary authority overseeing drug registration, quality, and importation, under the Ministry of Health.

3. How does Peru's patent law impact pharmaceutical innovation?
Limited patent linkage and data exclusivity make Peru more conducive for generics but pose challenges for innovative drug protection.

4. Can WHO prequalified products expedite registration in Peru?
Yes, recognition of WHO prequalification can streamline registration by reducing the need for extensive local data.

5. What opportunities exist for local manufacturing in Peru?
Government incentives, reduced import duties, and procurement policies favoring domestically produced medicines support local production investments.

References

[1] IQVIA, Pharmaceutical Market Data Latin America, 2022.
[2] Peruvian Ministry of Health (MINSA), General Law of Health (Ley N° 29344), 2010.
[3] DIGEMID, Regulatory Guidelines for Pharmaceuticals, 2022.
[4] World Intellectual Property Organization (WIPO), Patent Laws in Peru, 2021.
[5] PwC, Latin American Pharma Regulatory Landscape, 2022.